公开(公告)号：EP4335507A2

公开(公告)日：2024-03-13

申请号：EP23199180.3

申请日：2014-03-14

申请人： Aerie Pharmaceuticals, Inc.

发明人： KOPCZYNSKI, Casey ,  LIN, Cheng-Wen ,  STURDIVANT, Jill Marie ,  DELONG, Mitchell, A

IPC分类号： A61P27/06

摘要： Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：EP4218759A3

公开(公告)日：2023-09-06

申请号：EP23156661.3

申请日：2014-03-14

申请人： Aerie Pharmaceuticals, Inc.

发明人： KOPCZYNSKI, Casey ,  LIN, Cheng-Wen ,  STURDIVANT, Jill Marie ,  DELONG, Mitchell, A

IPC分类号： A61K31/47 ,  A61K31/557 ,  A61P27/06

摘要： Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：EP4218759A2

公开(公告)日：2023-08-02

申请号：EP23156661.3

申请日：2014-03-14

申请人： Aerie Pharmaceuticals, Inc.

发明人： KOPCZYNSKI, Casey ,  LIN, Cheng-Wen ,  STURDIVANT, Jill Marie ,  DELONG, Mitchell, A

IPC分类号： A61K31/47 ,  A61K31/557 ,  A61P27/06

摘要： Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：EP3773580A1

公开(公告)日：2021-02-17

申请号：EP19777599.2

申请日：2019-03-29

申请人： Aerie Pharmaceuticals, Inc.

发明人： DELONG, Mitchell A. ,  STURDIVANT, Jill M. ,  LICHOROWIC, Cynthia L. ,  LIN, Cheng-Wen

IPC分类号： A61K31/47 ,  C07D217/22

公开(公告)号：EP3506890A1

公开(公告)日：2019-07-10

申请号：EP17765001.7

申请日：2017-08-30

申请人： Aerie Pharmaceuticals, Inc.

发明人： LIN, Cheng-Wen ,  KOPCZYNSKI, Casey ,  DELONG, Mitchell, A. ,  STURDIVANT, Jill, M. ,  KRISHNAMOORTHY, Ramesh

IPC分类号： A61K31/00

公开(公告)号：EP4335507A3

公开(公告)日：2024-06-05

申请号：EP23199180.3

申请日：2014-03-14

申请人： Aerie Pharmaceuticals, Inc.

发明人： KOPCZYNSKI, Casey ,  LIN, Cheng-Wen ,  STURDIVANT, Jill Marie ,  DELONG, Mitchell, A

IPC分类号： A61K31/47 ,  A61K31/557 ,  A61P27/06

CPC分类号： A61K31/557 ,  A61K31/5575 ,  A61K31/559 ,  A61K31/4725 ,  A61K31/472 ,  C07D409/12 ,  C07D217/22 ,  A61K47/55 ,  A61P27/02 ,  A61P27/06 ,  A61P43/00 ,  A61K9/0048 ,  A61K9/08 ,  A61K47/10 ,  A61K47/26 ,  A61K31/47

摘要： Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：EP2571526A1

公开(公告)日：2013-03-27

申请号：EP11784089.2

申请日：2011-05-17

申请人： Aerie Pharmaceuticals, Inc.

发明人： KOPCZYNSKI, Casey ,  LIN, Cheng-Wen ,  SUTAY, Chris

IPC分类号： A61K47/32

CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61K31/00 ,  A61K31/215 ,  A61K47/32 ,  A61K47/36

摘要： Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

公开(公告)号：EP3934646A1

公开(公告)日：2022-01-12

申请号：EP20766052.3

申请日：2020-03-05

申请人： Aerie Pharmaceuticals, Inc.

发明人： DAS, Sanjib, Kumar ,  LIN, Cheng-Wen

IPC分类号： A61K31/472 ,  A61K47/34 ,  A61P27/02

公开(公告)号：EP2376058A1

公开(公告)日：2011-10-19

申请号：EP09796554.5

申请日：2009-12-18

申请人： Aerie Pharmaceuticals, Inc.

发明人： KOPCZYNSKI, Casey ,  LIN, Cheng-Wen ,  SUTAY, Chris

IPC分类号： A61K9/00 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36

CPC分类号： A61K9/0051 ,  A61K31/00

摘要： Drug delivery devices comprising a non-bioabsorbable polymer structure and a composition comprising an active agent have been discovered. The drug delivery devices may be used to treat ocular conditions, among other diseases and conditions. In addition, a method of treating an ocular condition has been discovered comprising implanting a drug delivery device which releases the active agent at a rate of Q = 0.001 x N x C wherein C is the topical effective concentration (in milligram/mL) of the active agent and N=0.01 to 0.5 for prostaglandins in their ester, amide, free acid or salt form, and N=0.5 to 5 for any active agent other than prostaglandins in their ester, amide, free acid or salt form.